There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atara Biotherapeutics (ATRA) and BioMarin Pharmaceutical (BMRN) with bullish sentiments.
Atara Biotherapeutics (ATRA)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics, with a price target of $70.00. The company’s shares closed last Wednesday at $12.82.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 24.8% and a 45.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Allogene Therapeutics.
Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $35.20, representing a 192.1% upside. In a report issued on August 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $26.00 price target.
See today’s analyst top recommended stocks >>
BioMarin Pharmaceutical (BMRN)
Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $95.00. The company’s shares closed last Wednesday at $76.72.
According to TipRanks.com, Gilson is a 5-star analyst with an average return of 35.1% and a 63.8% success rate. Gilson covers the Healthcare sector, focusing on stocks such as Homology Medicines, Stoke Therapeutics, and Ascendis Pharma.
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $117.95, representing a 37.5% upside. In a report issued on August 5, Piper Sandler also maintained a Buy rating on the stock with a $133.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
